Christopher S. Miller

Chris is a partner in the Health Care & Life Sciences, Technology and Private Equity groups at Troutman Pepper Locke.

He concentrates his practice in mergers and acquisitions, private equity, venture capital, and general corporate matters. His clients include private equity and venture capital firms, emerging companies, and public and private companies.

Chris represents domestic and foreign public and private companies and private equity funds in merger and acquisition transactions. He also represents private equity funds and emerging companies in venture capital, growth equity, and debt financing transactions. In addition, he counsels emerging companies in the life sciences, health care services, and technology industries in general corporate matters.

• Advised Center for Breakthrough Medicines Holdings, LLC (CBM) in its $350 million equity financing from an affiliate of SK Inc., the second largest conglomerate in South Korea, to create the world’s largest end-to-end cell and gene therapy contract development and manufacturing organization (CDMO).
• Advised Hikma Pharmaceuticals in its $425 million acquisition of Custopharm, a provider of generic sterile injectable products, from Water Street Healthcare Partners.
• Advised Hikma Pharmaceuticals in its $45.75 million acquisition of sterile injectable products from Teligent.
• Advised Biocoat, a specialty manufacturer of medical device coatings, in connection with a majority strategic investment by GTCR.
• Advised Pyramid Laboratories, a drug product contract development and manufacturing organization (CDMO), in connection with a growth investment from Audax.
• Advised Hidden River Strategic Capital in connection with its platform investment in Diamond Blade Warehouse, a distributor of diamond cutting tool products.
• Advised 1315 Capital in its acquisition of a majority interest in Homestead Smart Health Plans.
• Advised Analytical Wizards, a healthcare data analytics and technology company focused on the life sciences industry, in its $100 million acquisition by Definitive Healthcare.
• Advised Mavens, a provider of technology solutions for life sciences companies, in its acquisition by Komodo Health.
• Advised TrialScope, a clinical trial technology company, in its acquisition by Informa.
• Advised Core Avionics & Industrial Inc., a leading provider of development tools, software libraries, and deployable software packages that enable safety-critical GPU-based computing, including certified graphics rendering, autonomy, and AI applications, in its acquisition by Lynx Software Technologies, Inc.
• Advised Star2Star Communications, a cloud-based Unified Communications as as Service (UCaaS) provider, in its $437 million acquisition by Sangoma Technologies.
• Advised iPipeline, a provider of software solutions to the life insurance industry, in its acquisition by Thoma Bravo.
• Advised eMoney Advisor, a wealth planning software company, in its acquisition by Fidelity Investments.
• Advised Lynn Electronics, a manufacturer and supplier of custom fiber optic and copper assemblies for the data center and broadband markets, in its acquisition by NSi Industries.
• Advised Cenero, an audio visual technology, unified communications, and IT solutions provider, in its acquisition by Ricoh USA.
• Advised Apnimed, a clinical-stage pharmaceutical company focused on treatments for sleep apnea, in connection with its $150 million join venture Shionogi & Co. Ltd., a global research-driven pharmaceutical company based in Japan.
• Advised Apnimed, a clinical-stage pharmaceutical company focused on treatments for sleep apnea, in connection with its $62.5 million Series C financing led by Sectoral Asset Management.
• Advised Apnimed, a clinical-stage pharmaceutical company focused on treatments for sleep apnea, in connection with its $25 million Series B financing led by Morningside Ventures.
• Advised Palvella Therapeutics, a clinical-stage rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases, in its merger with Pieris Pharmaceuticals, Inc. and concurrent $78.9 million private placement. The combined company operates under the name Palvella Therapeutics, Inc. and its shares trade on the Nasdaq Capital Market.
• Advised Palvella Therapeutics, a clinical-stage rare disease biopharmaceutical company, in connection with its up to $37.7 million Series D financing led by Petrichor Healthcare Capital Management.
• Advised Palvella Therapeutics, a clinical-stage rare disease biopharmaceutical company, in connection with its $45 million Series C financing by investors including Samsara Biocapital, CAM Capital and BVF Partners.
• Advised Onkos Surgical, a provider of orthopedic oncology solutions, in connection with its $15 million Series C financing by investors including 1315 Capital and Canaan Partners.
• Advised Onkos Surgical, a provider of orthopedic oncology solutions, in connection with its $17.6 million Series B financing led by Canaan Partners.
• Advised Cagent Vasular, a manufacturer of angioplasty medical devices, in connection with its $30 million Series C financing led by U.S. Venture Partners.
• Advised Cagent Vascular, a manufacturer of angioplasty medical devices, in connection with its $9 million Series B financing led by Sectoral Asset Management.
• Advised Lokavant, a clinical trial intelligence platform company, in connection with an $8 million strategic investment from Mitsui & Co., Ltd., a global trading and investment company based in Japan.
• Advised NewSpring Capital in connection with a $15 million Series B financing of Jones, a vertical software company leading AI innovation in insurance verification.
• Advised NewSpring Capital in connection with a $50 million Series C financing of Cordial, a cross-channel marketing and data management provider.
• Advised NewSpring Capital in connection with a $48 million Series C financing of Celigo, an Integration Platform as a Service (iPaaS) provider.
• Advised NewSpring Capital in connection with a $40 million Series B financing of Bespoke Post, an e-commerce retailer.
• Advised NewSpring Capital in connection with a $32 million Series B financing of Enboarder, a people activation platform provider.
• Advised NewSpring Capital in connection with a $32 million Series B financing of Appcues, a user onboarding software provider.
• Advised AIMCOR Group in connection with its joint venture with AmeriLife Group.

• Best Lawyers in America®: Corporate Law (2026)
• Legal 500 United States: M&A/Corporate and Commercial: Venture Capital and Emerging Companies (2025)
• Chambers USA: Corporate/M&A: Private Equity, Pennsylvania (Philadelphia) (2019-2025), Startups & Emerging Companies, USA Nationwide (2025)